Cerus Announces Proposed Public Offering of Common Stock

  Cerus Announces Proposed Public Offering of Common Stock

Business Wire

CONCORD, Calif. -- March 13, 2013

Cerus Corporation (NASDAQ: CERS) today announced that it intends to offer and
sell shares of its common stock, subject to market and other conditions, in an
underwritten public offering. Cerus also expects to grant the underwriters a
30-day option to purchase additional shares of common stock to cover
overallotments, if any. Cerus anticipates using the net proceeds from the
offering for clinical development and other research and development
activities related to the INTERCEPT Blood System, preparatory activities for
the potential commercialization of the INTERCEPT Blood System in the United
States and elsewhere, and for other general corporate purposes, including
regulatory activity, selling, general and administrative expenses and working
capital. Cerus may also use a portion of the net proceeds from the offering to
prepay the remaining outstanding indebtedness under its growth capital loan
with Comerica Bank.

Cowen and Company, LLC is acting as sole book-running manager for the

The securities described above are being offered by Cerus pursuant to a shelf
registration statement previously filed with and declared effective by the
Securities and Exchange Commission (the “SEC”). A preliminary prospectus
supplement related to the offering will be filed with the SEC and will be
available on the SEC’s website located at http://www.sec.gov. Copies of the
preliminary prospectus supplement and the accompanying prospectus relating to
this offering, when available, may be obtained from Cowen and Company, LLC,
c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, New York
11717, Attn: Prospectus Department, or by calling 631-274-2806, or by faxing

This press release shall not constitute an offer to sell or the solicitation
of an offer to buy these securities, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other


Cerus Corporation is a biomedical products company focused on enhancing blood
safety. The INTERCEPT system is designed to reduce the risk of
transfusion-transmitted diseases by inactivating a broad range of pathogens
such as viruses, bacteria and parasites that may be present in donated blood.
The nucleic acid targeting mechanism of action enables INTERCEPT treatment to
inactivate established transfusion threats, such as hepatitis B and C, HIV,
West Nile virus and bacteria, and is designed to inactivate emerging pathogens
such as influenza, malaria and dengue. Cerus currently markets and sells the
INTERCEPT Blood System for both platelets and plasma in Europe, the
Commonwealth of Independent States, the Middle East and selected countries in
other regions around the world. In the United States, Cerus is seeking
regulatory approval of the INTERCEPT Blood System for plasma, and is in the
process of determining the application shell for a potential regulatory
submission for the INTERCEPT Blood System for platelets. The INTERCEPT red
blood cell system is in clinical development.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

This press release contains forward-looking statements. Any statements
contained in this press release that are not statements of historical fact may
be deemed to be forward-looking statements, including, without limitation,
statements relating to Cerus’ proposed public offering. These forward-looking
statements are based upon Cerus’ current expectations. Actual results could
differ materially from these forward-looking statements as a result of certain
factors, including, without limitation, risks related to whether Cerus will be
able to raise capital through the sale of shares of common stock, market
conditions and the satisfaction of customary closing conditions related to the
proposed public offering, risks related to the application of the net proceeds
from the proposed public offering, risks associated with the uncertain
research and product development process, and other risks detailed in Cerus'
filings with the SEC, including in Cerus' annual report on Form 10-K for the
year ended December 31, 2012, filed with the SEC on March 12, 2013. You are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date of this press release. Cerus does not
undertake any obligation to update any forward-looking statements as a result
of new information, future events, changed assumptions or otherwise.


Cerus Corporation
Kevin D. Green, 925-288-6138
Vice President, Finance and Chief Financial Officer
Press spacebar to pause and continue. Press esc to stop.